PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
Status:
Terminated
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
This is a single arm phase II trial assessing the potential activity of combination PEGPH20
plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic
adenocarcinoma.